WEHI lung macrophage RNA therapeutic

This preclinical RNA therapeutic program is a collaborative effort between the Walter and Eliza Hall Institute (WEHI) and Roche, aimed at treating Chronic Obstructive Pulmonary Disease (COPD) and other respiratory conditions. The technology utilizes lipid nanoparticles (LNPs) specifically engineered to deliver RNA molecules—such as mRNA or siRNA—to lung macrophages, which are key mediators of the inflammatory response in the airways. By targeting these cells directly, the therapy seeks to modulate the immune environment of the lung, potentially halting or reversing the progression of inflammatory damage. This approach leverages WEHI's expertise in macrophage biology and Roche's capabilities in RNA drug development and delivery.

Other names

Roche/WEHI respiratory RNA programLNP-delivered RNA for lung macrophagesWEHI lung macrophage RNA technology